OAS3
2'-5'-oligoadenylate synthase 3
Also known as: OAS3_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9Y6K5
- Gene
- OAS3
- Ensembl
- ENSG00000111331
- Chromosome
- 12
- Canonical length
- 1087 aa
- Protein class
- Enzymes, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Plasma membrane,Cytosol
OverviewNCBI Gene
This gene encodes an enzyme included in the 2', 5' oligoadenylate synthase family. This enzyme is induced by interferons and catalyzes the 2', 5' oligomers of adenosine in order to bind and activate RNase L. This enzyme family plays a significant role in the inhibition of cellular protein synthesis and viral infection resistance. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
1087 residues, UniProt reviewed canonical sequence.
>Q9Y6K5|OAS3
1 MDLYSTPAAA LDRFVARRLQ PRKEFVEKAR RALGALAAAL RERGGRLGAA APRVLKTVKG
61 GSSGRGTALK GGCDSELVIF LDCFKSYVDQ RARRAEILSE MRASLESWWQ NPVPGLRLTF
121 PEQSVPGALQ FRLTSVDLED WMDVSLVPAF NVLGQAGSGV KPKPQVYSTL LNSGCQGGEH
181 AACFTELRRN FVNIRPAKLK NLILLVKHWY HQVCLQGLWK ETLPPVYALE LLTIFAWEQG
241 CKKDAFSLAE GLRTVLGLIQ QHQHLCVFWT VNYGFEDPAV GQFLQRQLKR PRPVILDPAD
301 PTWDLGNGAA WHWDLLAQEA ASCYDHPCFL RGMGDPVQSW KGPGLPRAGC SGLGHPIQLD
361 PNQKTPENSK SLNAVYPRAG SKPPSCPAPG PTGAASIVPS VPGMALDLSQ IPTKELDRFI
421 QDHLKPSPQF QEQVKKAIDI ILRCLHENCV HKASRVSKGG SFGRGTDLRD GCDVELIIFL
481 NCFTDYKDQG PRRAEILDEM RAQLESWWQD QVPSLSLQFP EQNVPEALQF QLVSTALKSW
541 TDVSLLPAFD AVGQLSSGTK PNPQVYSRLL TSGCQEGEHK ACFAELRRNF MNIRPVKLKN
601 LILLVKHWYR QVAAQNKGKG PAPASLPPAY ALELLTIFAW EQGCRQDCFN MAQGFRTVLG
661 LVQQHQQLCV YWTVNYSTED PAMRMHLLGQ LRKPRPLVLD PADPTWNVGH GSWELLAQEA
721 AALGMQACFL SRDGTSVQPW DVMPALLYQT PAGDLDKFIS EFLQPNRQFL AQVNKAVDTI
781 CSFLKENCFR NSPIKVIKVV KGGSSAKGTA LRGRSDADLV VFLSCFSQFT EQGNKRAEII
841 SEIRAQLEAC QQERQFEVKF EVSKWENPRV LSFSLTSQTM LDQSVDFDVL PAFDALGQLV
901 SGSRPSSQVY VDLIHSYSNA GEYSTCFTEL QRDFIISRPT KLKSLIRLVK HWYQQCTKIS
961 KGRGSLPPQH GLELLTVYAW EQGGKDSQFN MAEGFRTVLE LVTQYRQLCI YWTINYNAKD
1021 KTVGDFLKQQ LQKPRPIILD PADPTGNLGH NARWDLLAKE AAACTSALCC MGRNGIPIQP
1081 WPVKAAVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against OAS3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.26
- Highest tissue expression
- 26 nTPM
Expression across tissuesHPA
Tissue
- salivary gland: 26 nTPM
- bone marrow: 20 nTPM
- spleen: 17 nTPM
- thymus: 15 nTPM
- urinary bladder: 13 nTPM
- lung: 12 nTPM
Single-cell type
- esophageal apical cells: 64 nCPM
- urothelial cells: 56 nCPM
- foveolar cells: 46 nCPM
- esophageal suprabasal cells: 38 nCPM
- extravillous trophoblasts: 36 nCPM
- ocular epithelial cells: 36 nCPM
Immune cell
- non-classical monocyte: 15 nTPM
- neutrophil: 9.7 nTPM
- classical monocyte: 7.8 nTPM
- intermediate monocyte: 7.4 nTPM
- myeloid DC: 4.1 nTPM
- total PBMC: 3.6 nTPM
Brain region
- spinal cord: 27 nTPM
- medulla oblongata: 22 nTPM
- pons: 16 nTPM
- thalamus: 11 nTPM
- midbrain: 9.5 nTPM
- amygdala: 8.4 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about OAS3.
Disease | ImmuneIEDB
Conditions an epitope on OAS3 was assayed in.
- type 1 diabetes mellitus T cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.27
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.26
- DepMap mean gene effect
- -0.08
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- antiviral innate immune response
- cellular response to exogenous dsRNA
- defense response to bacterium
- defense response to virus
- interleukin-27-mediated signaling pathway
- MDA-5 signaling pathway
- negative regulation of chemokine (C-C motif) ligand 5 production
- negative regulation of chemokine (C-X-C motif) ligand 2 production
- negative regulation of IP-10 production
- negative regulation of type I interferon-mediated signaling pathway
- negative regulation of viral genome replication
- nucleobase-containing compound metabolic process
- positive regulation of interferon-beta production
- positive regulation of monocyte chemotactic protein-1 production
- positive regulation of tumor necrosis factor production
- regulation of ribonuclease activity
- response to virus
- RIG-I signaling pathway
- type I interferon-mediated signaling pathway
- negative regulation of chemokine (C-X-C motif) ligand 9 production
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Polymerase, nucleotidyl transferase domain
- 2-5OAS/ClassI-CCAase, nucleotidyltransferase domain
- 2-5-oligoadenylate synthetase, C-terminal conserved site
- 2'-5'-oligoadenylate synthetase 1, domain 2/C-terminal
- 2-5-oligoadenylate synthetase, N-terminal conserved site
- Nucleotidyltransferase superfamily
- Nucleotidyltransferase domain
- 2'-5'-oligoadenylate synthetase 1, domain 2, C-terminus
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of OAS3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads OAS3 as an antibody target. Whether an autoantibody or antibody against OAS3 could matter depends on whether native OAS3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
OAS3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label OAS3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...